The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib + rituximab versus FCR in younger Chronic Lymphocytic Leukemia (CLL) patients
Published: 06 December 2018
Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment ...
Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, offers opinion on whether patients in the first line setting should ...
Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone ...
Michael Atkins, MD, regarding single agent TKIs in the 1st line setting
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...
Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look ...
Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination ...
Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, tell us about the results of KEYNOTE 365 investigating the use ...
Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...
Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on how androgen deprivation therapy (ADT) is changing for men ...
Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer ...
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
